PURPOSE: To determine the behaviour of serum levels of soluble E-selectin (sE-selectin), the soluble isoform of E-selectin, before/during/after therapy in patients with three. PATIENTS AND METHODS: Using commercially available ELISA kits, serum levels of sE-selectin have been determined in 15 patients with psoriasis, 15 with pemphigus vulgaris and 15 with bullous pemphigoid, and compared with those of 30 healthy subjects. RESULTS: The results showed increased serum levels of sE-selectin in the three groups of patients as compared with those of 30 healthy subjects (p <0.01). In addition, serum levels were significantly correlated with the disease activity expressed as Psoriasis Area and Severity Index (PASI score) (R = 0.56, p = 0.014) in psoriasis, and as number of the visible lesions (blisters/erosions), in the two bullous dermatoses (R = 0.81, p <0.01). After therapy, the marker levels were significantly decreased (p <0.01). CONCLUSIONS: Overall, these data suggest that serum determinations of sE-selectin could represent a clinically useful indicator to monitor therapy.
|Translated title of the contribution||Monitoring of sE-selectin serum levels in three different dermatoses|
|Number of pages||4|
|Publication status||Published - Jan 1998|
ASJC Scopus subject areas